Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage Study
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- cardiovascular prognosis
研究概览
简要总结
Acute coronary syndrome (ACS) is a lethal disease, reduced low-density lipoprotein (LDL) cholesterol due to inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9) reduces cardiovascular events and improve cardiovascular prognosis. we assuming that PCSK9 inhibitor could bring metabolic change in serum, in order to investigate the metabolic modification, we conduct this clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •New diagnosis ACS patient by serum biomarker and coronary arteriography.
排除标准
- •Severe renal dysfunction acute or chronic bacterial and viral infections sleep apnea cancer
研究组 & 干预措施
pcsk9 inhibitor group
patients with severe coronary stenosis diagnosed ACS. The baseline blood and urine would be collected, thereafter, the PCSK9 inhibitor would be injected. 64-72 hours after, the blood and urine sample collection would be performed.
干预措施: PCSK9 inhibitor (Drug)
结局指标
主要结局
cardiovascular prognosis
时间窗: 52 weeks
composite outcome of time to first occurrence of cardiovascular death, myocardial infarction, unstable angina and heart failure.
次要结局
未报告次要终点
研究者
Ying Li
professor
Shenzhen People's Hospital